Formation Bio
-57%
est. 2Y upside i
Formation Bio (FKA TrialSpark) is a tech-driven pharma company changing the way drug development is done.
Rank
#3714
Sector
Biotechnology
Est. Liquidity
~3Y
Data Quality
Data: HighFormation Bio operates in a high-potential, yet highly competitive and capital-intensive sector.
Last updated: March 10, 2026
Formation Bio successfully advances multiple acquired drug candidates through late-stage clinical trials, leading to lucrative licensing deals or a successful IPO at a $3.4B valuation. Key partnerships with Sanofi and OpenAI yield breakthrough AI applications, significantly de-risking and accelerating the pipeline.
The company makes steady progress with its pipeline, securing a few moderate licensing deals and demonstrating the efficiency of its AI platform. However, high R&D costs and intense competition temper valuation growth, leading to a $2.04B valuation at a liquidity event.
Formation Bio faces setbacks with key clinical trials or struggles to differentiate its AI platform amidst increasing competition from well-funded incumbents like Isomorphic Labs. This leads to challenges in securing further funding or a down round, resulting in a $1.02B valuation, significantly impacting common stock value due to liquidation preferences.
Preference Stack Risk
severeFunding Intensity
36%Investors hold $619M in liquidation preferences ahead of common stock.
Dilution Risk
highGiven the very high capital intensity of drug development and the strategy to acquire multiple assets, further funding rounds or significant dilution from existing preferences are likely before a profitable exit.
Secondary Liquidity
limitedSecondary market transactions are available for accredited investors, but not for the general public.
Other — 24 roles
- Associate Director, Bioanalytical Development · New York, NY; Boston, MA
- Associate Director, Drug Product Development · New York, NY; Boston, MA
- Associate Director, Drug Substance, Biologics · New York, NY; Boston, MA
- +21 more →
Last updated: March 10, 2026
Questions to Ask at the Interview
Strategic questions based on Formation Bio's data — designed to show you've done your homework.
- 1
“Given the high incumbent threat from major pharmaceutical companies and well-funded AI labs like Isomorphic Labs, how does Formation Bio plan to maintain its competitive edge and proprietary moat in the long term?”
- 2
“With a strategy to expand to 10-15 assets over the next 3-5 years, how is Formation Bio managing the capital intensity and potential dilution risks associated with advancing multiple drug candidates through clinical trials?”
- 3
“Considering the Series D funding and the current $1.7B valuation, what is the anticipated timeline and most likely path to a liquidity event (IPO or acquisition) for employees holding common stock or options?”
Community
Valuation Sentiment
Our model estimates -57% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.